essential thrombocythemia

Whether the patient has symptoms or other problems related to essential thrombocythemia.

The following revised diagnostic criteria for essential thrombocythemia were proposed in 2005.

Patients with essential thrombocythemia may have no symptoms.

Essential thrombocythemia often does not cause early symptoms.

Certain factors affect prognosis (chance of recovery) and treatment options for essential thrombocythemia.

Controversy is considerable regarding whether asymptomatic patients with essential thrombocythemia require treatment.

Other related entities include polycythemia vera, myelofibrosis, and essential thrombocythemia.

Essential thrombocythemia is a disease in which too many platelets are made in the bone marrow.

Untreated essential thrombocythemia means that a patient is newly diagnosed and has had no prior treatment except supportive care.

Treatment of essential thrombocythemia in patients younger than 60 years who have no symptoms and an acceptable platelet count is usually watchful waiting.

Essential thrombocythemia causes an abnormal increase in the number of platelets made in the blood and bone marrow.

However, essential thrombocythemia resembles polycythemia vera in that cells of the megakaryocytic series are more sensitive to growth factors.

Patients with p. vera and essential thrombocythemia have marked increases of red blood cell and platelet production, respectively.

In early 2000, she suffered the loss of both legs as a result of blood clots due to the rare blood disease essential thrombocythemia.

Essential thrombocythemia.

Tefferi A. Myeloproliferative disorders: essential thrombocythemia and primary myelofibrosis.

Essential thrombocythemia belongs to a group of diseases known as the myeloproliferative disorders (MPDs).

The proposed revised World Health Organization criteria for the diagnosis of essential thrombocythemia requires all four criteria.

A rare but classic symptom of polycythemia vera (and the related myeloproliferative disease essential thrombocythemia) is erythromelalgia.

Distinguishing prefibrotic myelofibrosis from essential thrombocythemia can be difficult because of substantial interobserver variability and because of no difference in clinical outcome.

G. Myeloproliferative neoplasms (especially chronic myelogenous leukemia; also polycythemia vera, primary myelofibrosis, essential thrombocythemia)

Three other disorders are commonly classified as MPDs: chronic myeloid leukemia, essential thrombocythemia and polycythemia vera.

The diagnosis of essential thrombocythemia requires the presence of a persistent thrombocytosis of greater than 600 x 10/ L in the absence of an alternative cause.

Mutations in JAK2 have been implicated in polycythemia vera, essential thrombocythemia, myelofibrosis as well as other myeloproliferative disorders.

Essential thrombocytosis (ET-Also known as Essential thrombocythemia) is a disorder characterized by extremely high numbers of circulating platelets.